Detection of Disease Progression in Advanced Glaucoma
晚期青光眼疾病进展的检测
基本信息
- 批准号:10359152
- 负责人:
- 金额:$ 37.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-01 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AffectAgeAlgorithm DesignAlgorithmic SoftwareAxonBayesian AnalysisBayesian ModelingBlindnessClinicalComplexComputer softwareDataDecision MakingDetectionDeteriorationDevelopmentDiagnosticDiseaseDisease ProgressionEarly DiagnosisEnrollmentEthnic OriginEyeFloorFutureGenderGlaucomaGoalsImageJointsLeadLinear RegressionsMeasurementMeasuresMethodsModelingMonitorNoiseOptic DiskOptical Coherence TomographyPatientsPatternPerformancePositioning AttributeProbabilityQuality of lifeReproducibilityResidual stateRetinaRetinal Ganglion CellsRetinal maculaSeveritiesSeverity of illnessSignal TransductionSoftware DesignStructureStructure-Activity RelationshipTestingThickTimeVisionVisitVisualVisual Fieldsadvanced diseaseage relatedbasecentral visual fieldclinical applicationclinical encountercohortdisabilityexperiencefollow-upfunctional lossfunctional outcomeshigh riskimprovedinclusion criterialongitudinal analysismaculameetingsnonlinear regressionnovelpatient populationpredictive modelingprospectiverate of changeretinal nerve fiber layersoftware developmenttime usetool
项目摘要
A pressing unmet need in the field of glaucoma diagnostics is to find methods for objective detection of
disease worsening or prediction of visual field (VF) progression in eyes with advanced disease. Eyes with
advanced glaucoma are at high risk of losing the remaining vision and blindness. Retinal nerve fiber layer
(RNFL) and optic nerve head measures reach their measurement floor as glaucoma progresses beyond the
early stages. Hence, functional assessment of the central VF is currently the main tool for monitoring advanced
glaucoma. Our central hypothesis is that assessment of the macular retinal ganglion cell (RGC)/axonal
complex can lead to improved detection or prediction of disease progression since the last RGCs to disappear
in glaucoma reside in the central retina (the macula). We will test this hypothesis in a cohort of glaucoma
subjects just reaching 5 years of follow-up and validate our methods in separate cohorts of glaucoma and
normal subjects. Aim 1. Are macular thickness measures able to detect change earlier and with a stronger
signal compared to RNFL measures in advanced glaucoma? We will measure progression rates for global and
local macular and RNFL measures within a Bayesian hierarchical framework. We will compare progression
rates and the proportion of progressing eyes/regions/sectors for macular and RNFL measures to normal eyes
and account for differing scales, age-related decay, and treatment. Aim 2A. Can macular OCT thickness
changes confirm and predict changes in central VFs for advanced glaucoma? We will estimate
longitudinal/temporal structure-function relationships with Bayesian joint hierarchical longitudinal modeling of
macular OCT and central 10° VF measures. These models will determine whether there is a contemporaneous
or lagged deterioration of OCT and VF. We will assess the influence of baseline disease severity, treatment
and other covariates on these joint longitudinal models. We will also compare the joint macular/central VF
models to joint models of RNFL and 24° VFs and develop functional prediction models from 1 to 4 years
ahead. Aim 2B. To validate the performance of prediction models, we will initiate a second prospectively
enrolled cohort of patients meeting similar inclusion criteria and matched to the original cohort by age, gender,
ethnicity and baseline glaucoma severity. We will compare VF point predictions (e.g., one- or two-visit step
ahead) to the observed VF data. Aim 3. Develop software for combining macular structural and functional data
in real time as a clinical tool for detection or prediction of progression. It will provide clinicians with
structural/functional rates of change and structural ‘step’ changes from baseline, and the probability and
distribution of predicted functional changes The information provided by the application can be used during a
clinical encounter to make decisions regarding ongoing management of glaucoma. Widespread real-time use
of our software will result in significant improvements in disease monitoring and timely treatment of progressive
glaucoma through advanced stages and will help reduce visual disability from glaucoma.
青光眼诊断领域中迫切的未满足的需求是找到客观检测青光眼的方法。
在患有晚期疾病的眼睛中,疾病恶化或预测视野(VF)进展。
晚期青光眼患者丧失剩余视力和失明的风险很高。视网膜神经纤维层
(RNFL)和视神经乳头测量达到其测量下限,因为青光眼进展超过
因此,中央VF的功能评估目前是监测晚期VF的主要工具。
我们的中心假设是黄斑视网膜神经节细胞(RGC)/轴突的评估,
复合物可以导致自最后一个RGC消失以来改善疾病进展的检测或预测
在青光眼中,视网膜色素瘤位于视网膜中央(黄斑)。我们将在一组青光眼患者中检验这一假设。
受试者刚刚达到5年的随访,并在不同的青光眼队列中验证我们的方法,
目的1.黄斑厚度测量是否能够更早地检测到变化,
晚期青光眼中RNFL指标的信号比较? 我们将测量全球和全球范围内的进展率,
在贝叶斯分层框架内的局部黄斑和RNFL测量。我们将比较进展
黄斑和RNFL测量的进展眼/区域/扇区与正常眼的比率和比例
并解释了不同的尺度,年龄相关的衰退,和治疗。
改变证实并预测晚期青光眼中央VF的改变? 我们估计
纵向/时间结构-功能关系与贝叶斯联合分层纵向建模
黄斑OCT和中央10° VF测量。这些模型将确定是否存在同时的
或OCT和VF的滞后恶化。我们将评估基线疾病严重程度、治疗
我们还将比较联合黄斑/中央VF
联合RNFL和24° VF模型,并开发1至4年的功能预测模型
目标2B.为了验证预测模型的性能,我们将前瞻性地启动第二个
符合相似入选标准并按年龄、性别
种族和基线青光眼严重程度。我们将比较VF点预测(例如, 一次或两次访视步骤
目的3.开发结合黄斑结构和功能数据的软件
作为检测或预测进展的临床工具。它将为临床医生提供
结构/功能变化率和相对于基线的结构“阶跃”变化,以及
预测功能变化的分布应用程序提供的信息可以在
广泛的真实的实时使用
我们的软件将导致疾病监测和及时治疗进展的显着改善
青光眼通过先进的阶段,并将有助于减少视力残疾青光眼。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kouros Nouri-Mahdavi其他文献
Kouros Nouri-Mahdavi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kouros Nouri-Mahdavi', 18)}}的其他基金
Detection of Disease Progression in Advanced Glaucoma
晚期青光眼疾病进展的检测
- 批准号:
10624322 - 财政年份:2020
- 资助金额:
$ 37.59万 - 项目类别:
Detection of Disease Progression in Advanced Glaucoma
晚期青光眼疾病进展的检测
- 批准号:
9888147 - 财政年份:2020
- 资助金额:
$ 37.59万 - 项目类别:
Detection of Glaucoma Progression with Macular OCT Imaging
利用黄斑 OCT 成像检测青光眼进展
- 批准号:
8675256 - 财政年份:2012
- 资助金额:
$ 37.59万 - 项目类别:
Detection of Glaucoma Progression with Macular OCT Imaging
利用黄斑 OCT 成像检测青光眼进展
- 批准号:
8866409 - 财政年份:2012
- 资助金额:
$ 37.59万 - 项目类别:
Detection of Glaucoma Progression with Macular OCT Imaging
利用黄斑 OCT 成像检测青光眼进展
- 批准号:
8529542 - 财政年份:2012
- 资助金额:
$ 37.59万 - 项目类别:
Detection of Glaucoma Progression with Macular OCT Imaging
利用黄斑 OCT 成像检测青光眼进展
- 批准号:
8353379 - 财政年份:2012
- 资助金额:
$ 37.59万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Continuing Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Standard Grant
The economics of (mis)information in the age of social media
社交媒体时代(错误)信息的经济学
- 批准号:
DP240103257 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Discovery Projects
How age & sex impact the transcriptional control of mammalian muscle growth
你多大
- 批准号:
DP240100408 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Discovery Projects
Supporting teachers and teaching in the age of Artificial Intelligence
支持人工智能时代的教师和教学
- 批准号:
DP240100111 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Discovery Projects
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
- 批准号:
502786 - 财政年份:2024
- 资助金额:
$ 37.59万 - 项目类别:
Directed Grant